Page 1

TSCAN THERAPEUTICS TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress August 19 , 2021 Debuted as Publicly Traded Company and Raised $ 100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR - T Therapy Candidates , TSC - 100 and TSC - 101 WALTHAM , Mass . , Aug. 19 , 2021 ( GLOBE NEWSWIRE ) -- TScan Therapeutics , Inc. ( Nasdaq : TCRX ) ( TScan or the Company ) , a biopharmaceutical company focused on the development of T - cell receptor ( TCR ) engineered T cell therapies ( TCR - T ) for the treatment of patients with cancer , today reported financial results for the quarter ended June 30 , 2021 , highlighted recent program progress , and outlined key upcoming milestones . " TScan achieved significant milestones this quarter , including the completion of our IPO that provided additional capital to execute on our long - term goals of advancing transformational TCR - T therapies for patients , " said David Southwell , Chief Executive Officer and President at TScan . " We are on track in advancing our early - stage pipeline of liquid and solid tumor TCR - T therapy candidates to the clinic . Specifically , we plan to complete IND - enabling studies for our lead liquid tumor candidates , TSC - 100 and TSC - 101 , and submit IND applications to the FDA during the fourth quarter . Additionally , we continue to progress our solid tumor program with the ongoing discovery of novel shared T cell targets and are advancing our TSC - 200 series candidates against four targets with a goal to treat patients with multiplexed therapy . " Second Quarter 2021 and Recent Business Highlights Financial and Corporate • In July 2021 , TScan completed its initial public offering ( IPO ) , raising $ 100 million in aggregate gross proceeds , before deducting underwriting discounts and commissions and offering expenses , and began trading on The Nasdaq Global Market . The IPO followed the closing of a Series C preferred stock financing of $ 100 million in gross proceeds in January 2021 . • In July 2021 , Gavin MacBeath , Ph.D. , TScan's Chief Scientific Officer , presented findings from TScan's work to discover the targets of T cells in recovering COVID - 19 patients at the Cell - Mediated Therapies for Infectious Disease Summit . The presentation also featured in vitro data comparing several polyepitope T - cell vaccine candidates based on the Company's novel T cell target discoveries . • In May 2021 , TScan appointed Brian M. Silver as Chief Financial Officer , and Gabriela Gruia M.D. , to its Board of Directors . Mr. Silver brings more than 25 years of diverse strategic and financial experience within the healthcare and investment banking sectors to TScan , including as a managing director in the healthcare group of Morgan Stanley , as a partner at Perella Weinberg Partners , and his most recent role as Chief Financial Officer at Freeline Therapeutics . Dr. Gruia is a seasoned oncology drug development executive with more than 25 years of global regulatory and research experience , including her prior role as Senior Vice President and Head of Regulatory Affairs for Novartis Oncology . TScan also named Timothy Barberich , the founder and former Chair and Chief Executive Officer of Sepracor Inc. , as Chair of TScan's Board of Directors . Upcoming Expected Milestones and Key Priorities Liquid Tumor Programs : TScan's two lead liquid tumor TCR - T therapy candidates , TSC - 100 and TSC - 101 , are designed to target HA - 1 and HA - 2 , respectively , and treat patients with hematological malignancies who are undergoing allogenic hematopoietic stem cell transplantation . • Present additional preclinical data of TSC - 100 and TSC - 101 during the fourth quarter of 2021 . • Complete Investigational New Drug ( IND ) -enabling studies and submit IND applications to the U.S. Food and Drug Administration ( FDA ) for TSC - 100 and TSC - 101 during the fourth quarter 2021 . • Initiate clinical trials for TSC - 100 and TSC - 101 in the first half of 2022 with initial top - line data expected in the second half of 2022 . Solid Tumor Programs : TScan's TSC - 200 series of TCR - T therapy candidates include a combination of known targets , such as HPV16 for TSC - 200 and PRAME for TSC - 203 , as well as targets that are novel antigens for TCR - T therapy , such as for TSC - 201 and TSC - 202 . • Present additional preclinical data of TSC - 200 series during the first half of 2022 .